Anti-FAP CAR T cells produced in vivo reduce fibrosis and restore liver homeostasis in metabolic dysfunction–associated steatohepatitis
Chittampalli N. Yashaswini(Icahn School of Medicine at Mount Sinai), Tyler E. Papp(Translational Therapeutics (United States)), Kenneth Li(Icahn School of Medicine at Mount Sinai), Adi Lightstone(Pharmanest (Sweden)), Bruno Cogliati(Universidade de São Paulo), Tran To(Icahn School of Medicine at Mount Sinai), Joel G. Rurik(Karolinska Institutet), Tianyue Qin(Icahn School of Medicine at Mount Sinai), J. A. Epstein(California Institute for Regenerative Medicine), Raisa Rasul(Pharmanest (Sweden)), Hamideh Parhiz(Translational Therapeutics (United States)), Haig Aghajanian(Therapeutics Clinical Research), Thomas Williamson(California Institute for Regenerative Medicine), Li Chen(Pharmanest (Sweden))
Cited by 14
Related Papers
CAR T Cells Produced in vivo to Treat Cardiac Injury
|HAL (Le Centre pour la Communication Scientifique Directe)|2023|940
Targeting cardiac fibrosis with engineered T cells
|Nature|2019|799
Plasticity of Hopx+ type I alveolar cells to regenerate type II cells in the lung
|Nature Communications|2015|309
Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs
|Molecular Therapy|2021|272